In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Central and Eastern Europe: Opportunity Abounds

Executive Summary

The size of the drug market in those Central and Eastern European countries set to join the European Union in May 2004 is no bigger than that of Canada and is smaller than any of the top five EU markets, for now. But growth in the region will continue to outstrip that in the West over the coming five years at least, according to IMS Global Consulting. The likely convergence of drug usage patterns with those in the West-particularly the increased use of innovative products-will add to the region's attractiveness. Many Big Pharma and mid-sized Europeans are already well placed to tap into the opportunity, but there's plenty of room for newcomers to join-particularly through acquisition.

You may also be interested in...



Senexis Ltd.

Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.

Private Device Companies Step-Up to the Public Market

Encouraged by successes in the biotech space, public market investors' interest in the device arena has returned in 2004 to support 10 companies' IPOs so far. Windhover's analysis of the valuations achieved indicate that private investors in these companies have, on average, enjoyed larger returns than their biotech counterparts.

Working Around Pre-Emption Rights

Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel